We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence (TREAT-UI)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02239796
First Posted: September 15, 2014
Last Update Posted: May 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
The Stroke Association, United Kingdom
University of Central Lancashire
Nursing, Midwifery & Allied Health Professions Research Unit
NHS Greater Glasgow and Clyde
NHS Lanarkshire
Information provided by (Responsible Party):
Glasgow Caledonian University
  Purpose
To aim of this study is to establish the feasibility of undertaking a phase III trial of transcutaneous posterior tibial nerve electrical stimulation (TPTNS) to alleviate stroke-related urinary incontinence.

Condition Intervention
Stroke Urinary Incontinence Device: NeuroTrac continence stimulators

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Feasibility Study for a Randomised Controlled Trial of Transcutaneous Posterior Tibial Nerve Stimulation to Alleviate Stroke-related Urinary Incontinence.

Resource links provided by NLM:


Further study details as provided by Glasgow Caledonian University:

Primary Outcome Measures:
  • Frequency of reported episodes of urinary incontinence as a measure of effectiveness. [ Time Frame: Up to 16 months ]

    Positive response to International Consultation on Incontinence Questionnaire-Urinary Incontinence Short-Form (ICIQ-UI SF).

    This outcome will be the primary outcome for a future full evaluation trial, should it prove feasible.



Secondary Outcome Measures:
  • Changes in the severity of urinary incontinence episodes experienced. [ Time Frame: Up to 16 months ]
  • Number of participants with adverse events as a measure of safety and tolerability. [ Time Frame: Up to 16 months ]
  • Changes in severity of urinary urgency, frequency and nocturia. [ Time Frame: Up to 16 months ]
    By completion of AUASI

  • Urinary symptoms experienced on the American Urological Association Symptom Index [ Time Frame: Up to 16 months ]
  • Mean Urgency Perception Scores recorded on a 3 day bladder diary [ Time Frame: Up to 16 months ]
  • Patient Perception of Bladder Condition [ Time Frame: Up to 16 months ]
  • Severity of bowel symptoms [ Time Frame: Up to 16 months ]
  • Patient Perception of Bowel Condition [ Time Frame: up to 16 months ]
  • Changes in post-void residual urine volume. [ Time Frame: Up to 16 months ]
  • Amount of urine leakage in 24 hours [ Time Frame: Up to 16 months ]
  • Participants perception of independence from any help with activities of daily living [ Time Frame: Up to 16 months ]
    Measured by completion of the Barthel Index Score and Modified Rankin Score.


Enrollment: 54
Study Start Date: September 2014
Study Completion Date: May 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TPTNS

12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.

Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps.

Device: NeuroTrac continence stimulators

Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.

Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators.

Sham Comparator: Sham TPTNS

The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.

The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.

The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided.

Device: NeuroTrac continence stimulators
We are using NeuroTrac continence stimulators.

Detailed Description:
Stroke-related urinary incontinence (UI) persists in more than one third of stroke survivors. It is associated with significant burden including reduced quality of life, increased morbidity and disability. Urgency UI, together with overactive bladder (OAB) symptoms (frequency, urgency, nocturia), is most commonly experienced. Current continence care is limited to lifestyle advice and behavioural interventions such as voiding programmes. There is a reliance on containment approaches and a lack of available options for active treatment. Intermittent electrical stimulation of the posterior tibial nerve (TPTNS) is effective for treating non-stroke neurogenic UI and OAB, but has not been tested in the stroke population. This pilot randomised controlled trial (RCT) aims to test the potential effectiveness of TPTNS for stroke-related bladder dysfunction. Adults with stroke-related UI will be randomised to TPTNS or sham. They and/or their carer will be taught to self-deliver a programme of TPTNS over a six week period. Bladder function, associated healthcare costs and quality of life outcomes will be measured at 6, 12 and 26 weeks. A nested process evaluation will be conducted. Pilot RCT and process evaluation results will inform the design of a phase III RCT of TPTNS to treat urinary incontinence in the stroke population.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women aged ≥ 18 years, with a diagnosis of stroke based on the WHO criteria (WHO 1989) and stroke-related urinary incontinence of at least once weekly.
  • Onset of stroke ≥ 4 weeks previously and discharged from hospital to own home following a new stroke episode within the previous 6 months.
  • Physically, cognitively and communicatively able and willing to learn to apply TPTNS or has carer who is able and willing to learn.

Exclusion Criteria:

  • Pre-existing urinary incontinence prior to stroke.
  • Current Urinary Tract Infection.
  • Voiding dysfunction requiring intermittent/indwelling catheterisation.
  • Cardiac pacemaker in situ.
  • Concurrent neurological diagnosis eg dementia, Multiple Sclerosis, diabetic neuropathy.
  • Reduced/absent sensation at electrode placement sites.
  • Post-void residual urine volume of > 150ml.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02239796


Locations
United Kingdom
NHS Ayrshire and Arran
Ayrshire, United Kingdom
NHS Lanarkshire
Glasgow, United Kingdom
Sponsors and Collaborators
Glasgow Caledonian University
The Stroke Association, United Kingdom
University of Central Lancashire
Nursing, Midwifery & Allied Health Professions Research Unit
NHS Greater Glasgow and Clyde
NHS Lanarkshire
Investigators
Principal Investigator: Joanne Booth Glasgow Caledonian University
  More Information

Responsible Party: Glasgow Caledonian University
ClinicalTrials.gov Identifier: NCT02239796     History of Changes
Other Study ID Numbers: TSA 2013/05
First Submitted: August 12, 2014
First Posted: September 15, 2014
Last Update Posted: May 26, 2016
Last Verified: February 2016

Keywords provided by Glasgow Caledonian University:
transcutaneous posterior tibial nerve stimulation
Randomised controlled trial
Feasibility

Additional relevant MeSH terms:
Stroke
Urinary Incontinence
Enuresis
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders